HC Andersen Capital: FDA approval of NeoNavia Q&A session with NeoDynamics, CEO Anna Eriksrud, and CFO Aaron Wong
HC Andersen Capital hosted a Q&A session with the management from NeoDynamics, CEO Anna Eriksrud, and CFO Aaron Wong. NeoDynamics recently received FDA approval for the promising NeoNavia™ pulse biopsy system in the US.Get a short update on the NeoNavia system, targeting the biopsy market with focus on breast cancer and how NeoDynamics will approach the US market. The company already has a strong management/organization in place in the US and is ready to launch the product with full commercialization in 2023. The CEO Anna Eriksrud updates you on why they got the approval so fast, and CFO